SCHEDULE 13G: Alpha Capital Anstalt Discloses 9.99% Stake in NanoVibronix Inc.

Alpha Capital Anstalt has reported a 9.99% beneficial ownership stake in NanoVibronix Inc., holding 82,471 shares of common stock.

Summary

• Alpha Capital Anstalt has filed a Schedule 13G, indicating beneficial ownership of NanoVibronix Inc. common stock.
• The reporting person, Alpha Capital Anstalt, is based in Liechtenstein.
• They beneficially own 82,471 shares of NanoVibronix Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• The percentage is calculated based on 825,533 shares outstanding as of April 29, 2025, as reported in NanoVibronix's Form S-1/A filed on May 14, 2025.
• Alpha Capital Anstalt has sole voting and dispositive power over all 82,471 shares.
• A contractual ownership restriction limits Alpha Capital Anstalt's beneficial control to 9.99%, even though the full conversion and/or exercise of their securities would exceed this limit.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by an institutional investor like Alpha Capital Anstalt is generally positive, indicating confidence. However, the contractual ownership restriction and the nature of a 13G filing (passive ownership, not operational results) temper the overall sentiment, making it moderately positive rather than strongly so.

Positives

• A significant institutional investor, Alpha Capital Anstalt, has taken a substantial stake in NanoVibronix Inc., potentially signaling confidence in the company.
• Alpha Capital Anstalt holds sole voting and dispositive power over its 9.99% stake, indicating direct control over their investment.

Negatives

• The existence of a contractual 9.99% ownership restriction suggests that Alpha Capital Anstalt's full potential ownership (from conversion/exercise of securities) is capped, which might limit their ability to increase their stake beyond this threshold without renegotiation or a different filing type.

Risks

• The document mentions that the full conversion and/or exercise of Alpha Capital Anstalt's securities would exceed the 9.99% ownership restriction, implying potential complexities or limitations related to their investment structure.

Future Outlook

The document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from NanoVibronix Inc. regarding its future outlook.

Industry Context

This filing indicates a significant investment by Alpha Capital Anstalt in NanoVibronix Inc., a company likely operating in the medical device or biotechnology sector given its name. Such an investment by an institutional entity can be seen as a vote of confidence in the company's prospects within its industry, potentially attracting further investor interest.

Comparison to Industry Standards

• This document is a beneficial ownership filing and does not provide financial or operational results that can be directly compared to industry standards or specific comparable companies/projects. It solely discloses an investor's stake.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially influence stock price positively due to perceived validation of the company's value.
• Company Management: Awareness of a large, passive shareholder may influence strategic decisions, though the 13G filing itself indicates no intent to influence control.

Next Steps

• The document does not outline any specific future actions, events, or milestones for NanoVibronix Inc. or Alpha Capital Anstalt beyond the filing itself.

Key Dates

Keywords

NanoVibronix Inc., Alpha Capital Anstalt, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Ownership Stake